Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2017
Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy.
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study.Annals of oncology : official journal of the European Society for Medical Oncology · 2017Trial
- Toll-like receptors: versatile players in tumor.Frontiers in immunology · 2026Review
- Involvement of nucleic acid-sensing toll-like receptors in human diseases and their controlling mechanisms.Journal of biomedical science · 2025Review
- Endoplasmic reticulum stress response pathway-mediated cell death in ovarian cancer.Frontiers in oncology · 2024Review
- Chemotherapeutic and targeted drugs-induced immunogenic cell death in cancer models and antitumor therapy: An update review.Frontiers in pharmacology · 2023Review
- "Open Sesame" to the complexity of pattern recognition receptors of myeloid-derived suppressor cells in cancer.Frontiers in immunology · 2023Review
- Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives.Biomarker research · 2022Review
- Potential pharmacologic interventions targeting TLR signaling in placental malaria.Trends in parasitology · 2022Review
- Toll-like receptor-targeted anti-tumor therapies: Advances and challenges.Frontiers in immunology · 2022Review
- Advances in Lipid-Based Nanoparticles for Cancer Chemoimmunotherapy.Pharmaceutics · 2021Review
- Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1.Frontiers in oncology · 2021Review
- Senescence in the Development and Response to Cancer with Immunotherapy: A Double-Edged Sword.International journal of molecular sciences · 2020Review
- Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes.European journal of medicinal chemistry · 2020Review
- Differential expression of immune related genes in high-grade ovarian serous carcinoma.Gynecologic oncology · 2020Article
- NF-κB Signaling in Ovarian Cancer.Cancers · 2019Review
- Recent clinical trends in Toll-like receptor targeting therapeutics.Medicinal research reviews · 2019Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.